Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
A recent study in A&R identifies an association between air pollutants, including fire smoke particulate matter, & both rheumatoid arthritis (RA) & RA-associated interstitial lung disease.
Exposure to air pollution, such as high levels of particulate matter from fire smoke and fossil fuel-related nitrogen oxides, may increase the risk of rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD), according to Kronzer et al. Their findings highlight the need for improved monitoring of air pollutants and suggest that addressing air pollution may help prevent RA and RA-associated ILD.
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
Pulmonary hypertension and Raynaud’s phenomenon are just some of the symptoms patients with systemic sclerosis (SSc) may experience. Here are insights into the diagnosis and management of SSc.
At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.
Experts provided insights into how precision medicine is being used to address the needs and care of patients with systemic sclerosis.
Brooks et al. evaluated the risk of lung cancer in patients with rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD) compared with the risk in matched controls without RA or RA-ILD. Understanding whether RA predisposes someone to lung cancer and whether patients with RA-ILD represent a uniquely high-risk group could inform cancer-screening strategies.
Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).
SAN DIEGO—In a scientific session at ACR Convergence 2023, Sindhu Johnson, MD, PhD, and Dinesh Khanna, MD, MSc, discussed ACR’s new guideline on SARDs and ILD.